GlassScriptPhysician profile
William O Lacy
NPI 1558457796
$6,056.45
in general payments reported to CMS, 2019-2025
27 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $246 · 2021: $666 · 2022: $641 · 2023: $878 · 2024: $564 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.51 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,352.03 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $829.27 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.90 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Inspire Medical Systems, INC. | $383.09 | 2023-2025 | Inspire |
| Mylan Specialty L.P. | $376.34 | 2019-2020 | |
| Insmed, INC. | $284.24 | 2019-2025 | Brinsupri, Arikayce |
| Jazz Pharmaceuticals INC. | $259.61 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $257.21 | 2023-2024 | Quviviq |
| Harmony Biosciences LLC | $208.38 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $200.99 | 2019-2025 | |
| Zoll Respicardia, INC. | $130.38 | 2025 | Remede System |
| Intuitive Surgical, INC. | $125.00 | 2021 | |
| Viatris Specialty LLC | $123.60 | 2025 | Yupelri |
| United Therapeutics Corporation | $119.70 | 2025 | |
| Pulmonx Corporation | $115.86 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $99.70 | 2019 | |
| Amgen INC. | $99.54 | 2022 | |
| Mallinckrodt Hospital Products INC. | $96.47 | 2022 | |
| Sunovion Pharmaceuticals INC. | $88.75 | 2019 | |
| Itamar Medical INC | $71.03 | 2025 | Watchpatone |
| Circassia INC. | $46.61 | 2019-2020 | |
| Shire North American Group INC | $40.28 | 2019 | |
| Genentech USA, INC. | $31.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.34 | 2019 | |
| Csl Behring | $26.75 | 2019 | |
| Electromed, INC. | $15.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lacy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.